Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: The YESTONO study

Clinical Drug Investigation

Volumn 27, Issue 12, 2007, Pages 841-849

  Schmidt, Andre C ^a   Graf, Christine ^b   Brixius, Klara ^b   Scholze, Juergen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b GERMAN SPORT UNIVERSITY COLOGNE   (Germany)

Author keywords

Antihypertensives, therapeutic use; Hypertension; Nebivolol, therapeutic use; Type 2 diabetes mellitus

Indexed keywords

HEMOGLOBIN A1C; LIPID; NEBIVOLOL;

ADD ON THERAPY; ADULT; AGED; ARTICLE; ASTHENIA; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FATIGUE; FEMALE; HEART RATE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; LIBIDO DISORDER; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; METABOLISM; MICROALBUMINURIA; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NIGHTMARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PERIPHERAL EDEMA; PHYSICAL CAPACITY; PRIORITY JOURNAL; PSORIASIS; STATISTICAL ANALYSIS; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 36348937221     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727120-00006     Document Type: Article

References (41)

1. Carter BL. Implementing the new guidelines for hypertension: JNC7, ADA, WHO-ISH. JMCP 2004; 10 Suppl. a: S18-25
2. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular disease in people with diabetes mellitus. Circulation 2007; 115: 114-26
3. Winer N, Sowers JR. Epidemiology of diabetes. J Clin Pharmacol 2004; 44: 397-405
4. Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC-7 report. JAMA 2003; 289: 2560-72
5. United Kingdom Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-13
6. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-62
7. Hansson L, Lindholm L, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-6
8. Eliasson B, Cederholm J, Nilsson P, et al. The gap between guidelines and reality: type 2 diabetes in a National Diabetes Register 1996-2003. Diabet Med 2005; 22: 1420-6
9. Buse JB, Ginsberg HN, Bakris GL, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114-26
10. Mancia G, De Backer G, Domminiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; 28: 1462-536
11. Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med 2004; 116 Suppl. A: 30S-8S
12. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs 1999; 57: 633-51
13. Bristow MR, Roden RL, Lowes BD, et al. The role of third-generation beta-blocking agents in chronic heart failure. Clin Cardiol 1998; 21 Suppl. 1: I3-13
14. Cockcroft JR, Chowienczyk PJ, Brett SE, et al. Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. J Pharmacol Exp Ther 1995; 274: 1067-71
15. Mangrella M, Rossi F, Fici F, et al. Pharmacology of nebivolol. Pharmacol Res 1998; 38: 419-31
16. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press 2004; 13 Suppl. 1: 17-32
17. Ritter JM. Nebivolol: endothelium-mediated vasodilating effect. J Cardiovasc Pharmacol 2001; 38: S13-6
18. Duprez D, Lefebvre R, De Backer T, et al. Influence of nebivolol on the cardiovascular hemodynamics during postural changes and isometric exercise. Cardiovasc Drugs Ther 1991; 5: 709-17
19. Dessy C, Saliez J, Ghisdal P, et al. Endothelial beta3-adrenoreceptors mediate nitric oxide-dependent vasorelaxation of coronary microvessels in response to the third-generation beta-blocker nebivolol. Circulation 2005; 112: 1198-205
20. Van Bortel LM, Breed JG, Joosten J, et al. Nebivolol in hypertension: a double-blind placebo-controlled multicenter study assessing its antihypertensive efficacy and impact on quality of life. J Cardiovasc Pharmacol 1993; 21: 856-62
21. Van Bortel LM, Bulpitt CJ, Fici F. Quality of life and antihypertensive effect with nebivolol and losartan. Am J Hypertens 2005; 18: 1060-6
22. Predel HG, Mainka W, Schillings W, et al. Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance energy metabolism, cardiovascular and neurohumoral parameters in physically active patients with arterial hypertension. J Hum Hypertens 2001; 15: 715-21
23. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation β-blocker. Blood Pressure 2004; 13 Suppl. 1: 3-17
24. Lithel HO. Effect of antihypertensive drugs on insulin, glucose, and lipid metabolism. Diabetes Care 1991; 14: 203-9
25. Majumdar SR. Beta-blockers for the treatment of hypertension in patients with diabetes: exploring the contraindication myth. Cardiovasc Drugs Ther 1999; 13: 435-439
26. Pessina C. Metabolic effects and safety profile of nebivolol. J Pharmacol 2001; 38 Suppl. 3: 33-5
27. Pasini AF, Garbin U, Narva MC, et al. Nebivolol decreases oxidative stress in essential hypertensive patients and decreases nitric oxide by reducing its oxidative inactivation. J Hypertens 2005; 23: 589-96
28. Lacourcìere Y, Poirier L, Lefebvre J. Comparative effects of a new cardioselective beta-blocker nebivolol and nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoproteins. J Clin Pharmacol 1992; 32: 660-6
29. Peter P, Martin U, Sharma A, et al. Effect of treatment with nebivolol on parameters of oxidative stress in type 2 diabetics with mild to moderate hypertension. J Clin Pharm Ther 2006;31: 153-9
30. Poirier L, Cleroux J, Nadeau A, et al. Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. J Hypertens 2001; 19: 1429-35
31. Korotkoff MS. On the subject of methods of determining blood pressure. Bull Imperial Mil Med Acad 1905; 11: 365
32. What is obesity? American Obesity Association [online]. Available from URL: http://www.obesity.org/subs/fastfacts/obesity_what2.shtml [Accessed 2007 Nov 8]
33. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 2000; 321: 412-9
34. Domanksi MJ, Davis BR, Pfeffer MA, et al. Isolated systolic hypertension: prognostic information provided by pulse pressure. Hypertension 1999; 34: 375-80
35. Franklin SS, Khan SA, Wong D, et al. Increased pulse pressure useful in predicting risk for conronary heart disease? The Framingham Heart Study. Circulation 1999; 100: 354-60
36. Glynn RJ, Chae CU, Guralnik J, et al. Pulse pressure and mortality in older people. Arch Intern Med 2000; 160: 2765-772
37. Fogari R, Zoppi A, Lazzari P, et al. Comparative effects of nebivolol and atenolol on blood pressure and insulin sensitivity in hypertensive subjects with type II diabetes. J Hum Hypertens 1997; 11: 753-7
38. Kaiser T, Heise T, Nosek L, et al. Influence of nebivolol and enalapril on metabolic parameters and arterial stiffness in hypertensive type 2 diabetic patients. J Hypertens 2006; 24: 1397-403
39. Ladage D, Brixius K, Hoyer H, et al. Mechanisms underlying nebivolol-induced endothelial nitric oxide synthase activation in human umbilical vein endothelial cells. Clin Exp Pharmacol Physiol 2006; 33: 720-4
40. Rozec B, Quang TT, Noireaud J, et al. Mixed beta3-adrenoceptor agonist and alpha1-adrenoceptor antagonist properties of nebivolol in rat thoracic aorta. Br J Pharmacol 2006; 147: 699-706
41. De Groot AA, Mathy MJ, van Zwieten PA, et al. Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta. J Cardiovasc Pharmacol 2003; 42: 232-6